![]() ![]() ![]() Lymphopenias were observed in 84.6% of patients receiving vemurafenib and dexamethasone. Dexamethasone co-administration further diminished lymphocyte counts. Dabrafenib treated patients only rarely demonstrated lymphopenia (12.5%). Vemurafenib treatment led to a considerable decrease in lymphocyte cell counts, with 62.3% of patients having lymphopenia. Additionally, the number and severity of infections occurring in these groups was analyzed. The amount of patients receiving either medication with or without systemic corticosteroids (dexamethasone) was determined and lymphocyte counts before and under therapy assessed. A cohort of 102 patients receiving either the selective BRAF inhibitor vemurafenib or dabrafenib was analyzed. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and predisposes to infection was investigated. We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. Sondermann, Wiebke Griewank, Klaus G Schilling, Bastian Livingstone, Elisabeth Leyh, Julia C Rompoti, Natalia Cosgarea, Ioana Schimming, Tobias Schadendorf, Dirk Zimmer, Lisa Hillen, Uwe Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |